Development of OTT166 an RGD-Binding Integrin Antagonist for the Topical Treatment of Diabetic Retinopathy

Time: 4:10 pm
day: Day One


  • Distributes to posterior segment of the eye after eye drop administration
  • Reduces neovascularization and vessel leakage in multiple animal models of diabetic retinopathy and wet-AMD
  • Phase 1 clinical data show safety and tolerability and evidence of biological activity – proceeding to Phase 2